Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia

Here we present the 3-year results of ZUMA-4, a phase I/II multicenter study evaluating the safety and efficacy of KTEX19, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in pediatric/adolescent patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Phase I e...

Descripció completa

Dades bibliogràfiques

Autors principals:	Alan S. Wayne, Van Huynh, Nobuko Hijiya, Rayne H. Rouce, Patrick A. Brown, Joerg Krueger, Carrie L. Kitko, Edward Dela Ziga, Michelle L. Hermiston, Michael K. Richards, Andre Baruchel, Petra C. Schuberth, John Rossi, Lang Zhou, Lovely Goyal, Rajul Jain, Remus Vezan, Behzad Kharabi Masouleh, Daniel W. Lee
Format:	Artigo
Idioma:	Inglês
Publicat:	Ferrata Storti Foundation 2022-10-01
Col·lecció:	Haematologica
Accés en línia:	https://haematologica.org/article/view/10837
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!